Compare Analog Devices, Inc. (ADI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs TransMedics Group Inc — how do they compare? Analog Devices, Inc. trades at $384 (market cap $187.67B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Analog Devices, Inc. is far larger — about 60.5× TransMedics Group Inc's market cap, and Analog Devices, Inc. pays a 1.14% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ADI | TMDX | |
|---|---|---|
Market Cap | $187.67B | $3.10B |
Sector | Technology | Technology |
52-Week High | $445.48 | $150.42 |
52-Week Low | $225.20 | $61.99 |
Enterprise Value | $192.92B | $3.49B |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $384.98, up 0.27% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $472.29 highlight positive momentum. The company maintains robust profitability with a 26.01% net income margin and a dividend payout of $1.10, supported by solid cash flow from operations of $4.81 billion in 2025.
Outlook remains favorable with projected revenue growth to $12.7 billion in 2026, though elevated valuation ratios and competitive pressures in semiconductors pose risks. Institutional buying and a lack of sell ratings underscore confidence, but investors should monitor debt levels and market volatility.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
